A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

In its early stages, simple fatty liver (steatosis) is relatively harmless and reversible. However, if liver fat continues to accumulate, it can lead to non-alcoholic steatohepatitis (NASH), a ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

NASH kNOWledge, a non-profit corporation established to provide education and increase public awareness of non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), recently ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even liver ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even liver ...

but untreated disease can progress to severe conditions such as non-alcoholic steatohepatitis (NASH), cirrhosis, or liver cancer.” Although no specific drugs are approved yet for treating NAFLD ...

If left untreated, NAFLD can progress into a more serious form known as non-alcoholic steatohepatitis (NASH), which can cause chronic inflammation, liver scarring, and even liver cancer.

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...